tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2021-99-2-58-66tiblj-1513Research ArticleОБЗОРЫREVIEWSДеламанид – новый противотуберкулезный препарат: применение, ограничения, перспективыDelamanid is a new anti-tuberculosis drug: use, limitations, and prospectsЗиминаВ. Н.ZiminaV. N.

Зимина Вера Николаевна, доктор медицинских наук, профессор кафедры инфекционных болезней с курсами эпидемиологии и фтизиатрии медицинского института

117198, Москва, ул. Миклухо-Маклая, д. 6

Vera N. Zimina, Doctor of Medical Sciences, Professor of the Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology of the Medical Institute

6, Miklukho-Maklaya St., Moscow, 117198

vera-zim@yandex.ruhttps://orcid.org/0000-0002-5826-5517ВиктороваИ. Б.ViktorovaI. B.

Викторова Ирина Борисовна, кандидат медицинских наук, доцент кафедры фтизиопульмонологии

654005, г. Новокузнецк, пр. Строителей, д. 5

Irina B. Viktorova, Candidate of Medical Sciences, Associate Professor of Phthisiopulmonology Department

5, Stroiteley Ave., Novokuznetsk, 654005

irinaviktoroff@mail.ruРоссийский университет дружбы народов; ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияPeoples’ Friendship University of Russia; National Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian FederationНовокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияNovokuznetsk State Institute for Doctors' Professional Development – Branch of Russian Medical Academy of Continuing Professional EducationRussian Federation2021100320219925866Copyright © Зимина В.Н., Викторова И.Б., 20212021Зимина В.Н., Викторова И.Б.Zimina V.N., Viktorova I.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1513

В обзоре представлен анализ 61 публикации об использовании деламанида ‒ нового препарата для лечения лекарственно-резистентного туберкулеза. Приведены сведения об особенностях фармакокинетики, эффективности и безопасности, а также месте деламанида в составе комбинированной терапии туберкулеза с множественной лекарственной устойчивостью. Представлены особенности применения деламанида у детей и больных ВИЧ-инфекцией.

The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination therapy of multiple drug resistant tuberculosis. It tells about specific parameters of delamanid use in children and HIV patients.

деламанидтуберкулезлекарственная устойчивость микобактерий туберкулезаВИЧ-инфекцияdelamanidtuberculosisdrug resistance of Mycobacterium tuberculosisHIV infectionReferencesГайда А. И., Свешникова О. М., Верховая В. Н., Махмаева С. В., Никишова Е. И., Марьяндышев А. О. Лечение больных туберкулезом с широкой лекарственной устойчивостью микобактерий с применением новых противотуберкулезных препаратов в гражданском обществе Архангельской области // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 7. ‒ С. 5-10. https://doi.org/10.21292/2075-1230-2018-96-7-5-10.Gayda А.I., Sveshnikova O.M., Verkhovaya V.N., Makhmaeva S.V., Nikishova E.I., Maryandyshev А.O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-7-5-10.Лорсанов С. М., Хайдарханова З. Б., Хункарсултанов С. Б. Опыт применения деламанида в Чеченской Республике // Туб. и болезни легких. ‒ 2019. ‒ Т. 97, № 12. ‒ С. 62-63. https://doi.org/10.21292/2075-1230-2019-97-12-62-63.Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B. The experience of using delamanid in the Chechen Republic. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 12, pp. 62-63. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-12-62-63.Марьяндышев А. О., Лорсанов С. М., Хайдарханова З. Б., Хункарсултанов С. Б., Перхин Д. В., Свешникова О. М., Гайда А. И., Привольнев В. В. Результаты применения деламанида в лечении туберкулеза с множественной и широкой лекарственной устойчивостью возбудителя в Российской Федерации // Туб. и болезни легких. ‒ 2019. ‒ Т. 97, № 11. ‒ С. 67-68. https://doi.org/10.21292/2075-1230-2019-97-11-67-68.Maryandyshev А.O., Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B., Perkhin D.V., Sveshnikova O.M., Gayda А.I., Privolnev V.V. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 67-68. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-11-67-68.A 6-month safety, efficacy and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis (Protocol 242-12-233), 2013. [NCT01859923] https://clinicaltrials.gov/ct2/show/NCT01859923.A 6-month safety, efficacy and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis (Protocol 242-12-233), 2013. [NCT01859923] https://clinicaltrials.gov/ct2/show/NCT01859923.Akkerman O., Aleksa A., Alffenaar J. W., Al-Marzouqi N. H., Arias-Guillén M., Belilovski E., Bernal E., Boeree M. J., Borisov S. E., Bruchfeld J., Cadiñanos Loidi J., Cai Q., Caminero J. A., Cebrian Gallardo J. J., Centis R., Codecasa L. R., D'Ambrosio L., Dalcolmo M., Danila E., Dara M., Davidavičienė E., Davies Forsman L., De Los Rios Jefe J., Denholm J., Duarte R., Elamin S. E., Ferrarese M., Filippov A., Ganatra S., Garcia A., García-García J. M., Gayoso R., Giraldo Montoya A. M., Gomez Rosso R. G., Gualano G., Hoefsloot W., Ilievska-Poposka B., Jonsson J., Khimova E., Kuksa L., Kunst H., Laniado-Laborín R., Li Y., Magis-Escurra C., Manfrin V., Manga S., Marchese V., Martínez Robles E., Maryandyshev A., Matteelli A., Migliori G. B., Mullerpattan J. B., Munoz-Torrico M., Mustafa Hamdan H., Nieto Marcos M., Noordin N. M., Palmero D. J., Palmieri F., Payen M. C., Piubello A., Pontali E., Pontarelli A., Quirós S., Rendon A., Skrahina A., Šmite A., Solovic I., Sotgiu G., Souleymane M. B., Spanevello A., Stošić M., Tadolini M., Tiberi S., Udwadia Z. F., van den Boom M., Vescovo M., Viggiani P., Visca D., Zhurkin D., Zignol M., members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study // Int. J. Infect. Dis. ‒ 2019. ‒ Vol. 83. ‒ Р. 72-76. doi: 10.1016/j.ijid.2019.03.036. Epub. 2019 Apr 3. PMID: 30953827.Akkerman O., Aleksa A., Alffenaar J. W., Al-Marzouqi N. H., Arias-Guillén M., Belilovski E., Bernal E., Boeree M. J., Borisov S. E., Bruchfeld J., Cadiñanos Loidi J., Cai Q., Caminero J. A., Cebrian Gallardo J. J., Centis R., Codecasa L. R., D'Ambrosio L., Dalcolmo M., Danila E., Dara M., Davidavičienė E., Davies Forsman L., De Los Rios Jefe J., Denholm J., Duarte R., Elamin S. E., Ferrarese M., Filippov A., Ganatra S., Garcia A., García-García J. M., Gayoso R., Giraldo Montoya A. M., Gomez Rosso R. G., Gualano G., Hoefsloot W., Ilievska-Poposka B., Jonsson J., Khimova E., Kuksa L., Kunst H., Laniado-Laborín R., Li Y., Magis-Escurra C., Manfrin V., Manga S., Marchese V., Martínez Robles E., Maryandyshev A., Matteelli A., Migliori G. B., Mullerpattan J. B., Munoz-Torrico M., Mustafa Hamdan H., Nieto Marcos M., Noordin N. M., Palmero D. J., Palmieri F., Payen M. C., Piubello A., Pontali E., Pontarelli A., Quirós S., Rendon A., Skrahina A., Šmite A., Solovic I., Sotgiu G., Souleymane M. B., Spanevello A., Stošić M., Tadolini M., Tiberi S., Udwadia Z. F., van den Boom M., Vescovo M., Viggiani P., Visca D., Zhurkin D., Zignol M., members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study // Int. J. Infect. Dis. ‒ 2019. ‒ Vol. 83. ‒ Р. 72-76. doi: 10.1016/j.ijid.2019.03.036. Epub. 2019 Apr 3. PMID: 30953827.Alvarez-Uria G., Midde M., Pakam R., Naik P. K. Diagnostic and prognostic value of serum albumin for tuberculosis in HIV infected patients eligible for antiretroviral therapy: datafrom an HIV cohort study in India // Bioimpacts. ‒ 2013. ‒ Vol. 3, № 3. ‒ P. 123-128.Alvarez-Uria G., Midde M., Pakam R., Naik P. K. Diagnostic and prognostic value of serum albumin for tuberculosis in HIV infected patients eligible for antiretroviral therapy: datafrom an HIV cohort study in India // Bioimpacts. ‒ 2013. ‒ Vol. 3, № 3. ‒ P. 123-128.Barry P. J., O'Connor T. M. Novel agents in the management of Mycobacterium tuberculosis disease // Curr. Med. Chem. ‒ 2007. ‒ Vol. 14, № 18. ‒ Р. 2000-2008. doi:10.2174/092986707781368496.Barry P. J., O'Connor T. M. Novel agents in the management of Mycobacterium tuberculosis disease // Curr. Med. Chem. ‒ 2007. ‒ Vol. 14, № 18. ‒ Р. 2000-2008. doi:10.2174/092986707781368496.Blair H. A., Scott L. J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis // Drugs. ‒ 2015. ‒ Vol. 75, № 1. ‒ Р. 91-100.Blair H. A., Scott L. J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis // Drugs. ‒ 2015. ‒ Vol. 75, № 1. ‒ Р. 91-100.Conradie F., Diacon A. H., Ngubane N., Howell P., Everitt D., Crook A. M., Mendel C. M., Egizi E., Moreira J., Timm J., McHugh T. D., Wills G. H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M., Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2020. ‒ Vol. 382, № 10. ‒ Р. 893-902. doi: 10.1056/NEJMoa1901814. PMID: 32130813; PMCID: PMC6955640.Conradie F., Diacon A. H., Ngubane N., Howell P., Everitt D., Crook A. M., Mendel C. M., Egizi E., Moreira J., Timm J., McHugh T. D., Wills G. H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M., Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2020. ‒ Vol. 382, № 10. ‒ Р. 893-902. doi: 10.1056/NEJMoa1901814. PMID: 32130813; PMCID: PMC6955640.D'Ambrosio L., Centis R., Tiberi S., Tadolini M., Dalcolmo M., Rendon A., Esposito S., Migliori, G. B. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review // J. Thorac. Dis. ‒ 2017. ‒ Vol. 9, № 7. ‒ Р. 2093-2101. https://doi.org/10.21037/jtd.2017.06.16.D'Ambrosio L., Centis R., Tiberi S., Tadolini M., Dalcolmo M., Rendon A., Esposito S., Migliori, G. B. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review // J. Thorac. Dis. ‒ 2017. ‒ Vol. 9, № 7. ‒ Р. 2093-2101. https://doi.org/10.21037/jtd.2017.06.16.Dooley K. E., Rosenkranz S. L., Conradie F. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the deliberate trial. CROI. 2019.Dooley K. E., Rosenkranz S. L., Conradie F. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the deliberate trial. CROI. 2019.Esmail A., Sabur N. F., Okpechi I., Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill // J. Thorac. Dis. ‒ 2018. ‒ Vol. 10, № 5. ‒ Р. 3102-3118. doi:10.21037/jtd.2018.05.11.Esmail A., Sabur N. F., Okpechi I., Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill // J. Thorac. Dis. ‒ 2018. ‒ Vol. 10, № 5. ‒ Р. 3102-3118. doi:10.21037/jtd.2018.05.11.Esposito S., D'Ambrosio L., Tadolini M., Schaaf H. S., Caminero Luna J., Marais B., Centis R., Dara M., Matteelli A., Blasi F., Migliori G. B. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use // Eur. Respir. J. ‒ 2014. ‒ Vol. 44. ‒ Р. 811-815.Esposito S., D'Ambrosio L., Tadolini M., Schaaf H. S., Caminero Luna J., Marais B., Centis R., Dara M., Matteelli A., Blasi F., Migliori G. B. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use // Eur. Respir. J. ‒ 2014. ‒ Vol. 44. ‒ Р. 811-815.European Medicines Agency. Assessment Report: Deltyba. London: European Medicines Agency; 2014 https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf.European Medicines Agency. Assessment Report: Deltyba. London: European Medicines Agency; 2014 https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf.Ferlazzo G., Mohr E., Laxmeshwar C. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of drug-resistant tuberculosis patients in Armenia, India and South Africa: a retrospective cohort study // Lancet Infect. Dis. ‒ 2018. ‒ Vol. 18. ‒ Р. 536-544.Ferlazzo G., Mohr E., Laxmeshwar C. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of drug-resistant tuberculosis patients in Armenia, India and South Africa: a retrospective cohort study // Lancet Infect. Dis. ‒ 2018. ‒ Vol. 18. ‒ Р. 536-544.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E., Gao M., Awad M., Park S. K., Shim T. S., Suh G. Y., Danilovits M., Ogata H., Kurve A., Chang J., Suzuki K., Tupasi T., Koh W. J., Seaworth B., Geiter L. J., Wells C. D. Delamanid for multidrug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2012. ‒ Vol. 366, № 23. ‒ Р. 2151‐2160.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E., Gao M., Awad M., Park S. K., Shim T. S., Suh G. Y., Danilovits M., Ogata H., Kurve A., Chang J., Suzuki K., Tupasi T., Koh W. J., Seaworth B., Geiter L. J., Wells C. D. Delamanid for multidrug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2012. ‒ Vol. 366, № 23. ‒ Р. 2151‐2160.Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.Groll A. H., Mickiene D., Petraitis V., Petraitiene R., Ibrahim K. H., Piscitelli S. C., Bekersky I., Walsh T. J. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits // Antimicrob. Agents. Chemother. ‒ 2001. ‒ Vol. 45, № 12. ‒ Р. 3322-3327.Groll A. H., Mickiene D., Petraitis V., Petraitiene R., Ibrahim K. H., Piscitelli S. C., Bekersky I., Walsh T. J. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits // Antimicrob. Agents. Chemother. ‒ 2001. ‒ Vol. 45, № 12. ‒ Р. 3322-3327.Guglielmetti L., Barkane L., Le Dû D., Marigot-Outtandy D., Veziris N., Yazdanpanah Y., Kuksa L., Caumes E., Fréchet-Jachym M. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 3. ‒ Р. 1702550. Published 2018 Mar 22. doi:10.1183/13993003.02550-2017.Guglielmetti L., Barkane L., Le Dû D., Marigot-Outtandy D., Veziris N., Yazdanpanah Y., Kuksa L., Caumes E., Fréchet-Jachym M. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 3. ‒ Р. 1702550. Published 2018 Mar 22. doi:10.1183/13993003.02550-2017.Hafkin J., Frias M., Hesseling A., Garcia-Prats A. J., Schaaf H. S., Gler M. et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6-17 years. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. [Poster A-960]. San Diego, CA, USA: ICAAC, 17-25 September 2015. 28.Hafkin J., Frias M., Hesseling A., Garcia-Prats A. J., Schaaf H. S., Gler M. et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6-17 years. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. [Poster A-960]. San Diego, CA, USA: ICAAC, 17-25 September 2015. 28.Hafkin J., Frias M., De Leon A., Hittel N., Geiter L., Wells C., et al. Long-term safety, tolerability, and pharmacokinetics of delamanid in children ages 12-17. EP-115-04. Presentation at 46th Union World Conference on Lung Health Cape Town, South Africa, 2-6 December 2015 // Int. J. Tuberc. Lung Dis. ‒ 2015. ‒ Vol. 19 (12 Suppl. 2): S91. [EP-115-04].Hafkin J., Frias M., De Leon A., Hittel N., Geiter L., Wells C., et al. Long-term safety, tolerability, and pharmacokinetics of delamanid in children ages 12-17. EP-115-04. Presentation at 46th Union World Conference on Lung Health Cape Town, South Africa, 2-6 December 2015 // Int. J. Tuberc. Lung Dis. ‒ 2015. ‒ Vol. 19 (12 Suppl. 2): S91. [EP-115-04].Harausz E. P., Garcia-Prats A. J., Seddon J. A., Schaaf H. S., Hesseling A. C., Achar J., Bernheimer J., Cruz A. T., D'Ambrosio L., Detjen A., Graham S. M., Hughes J., Jonckheere S., Marais B. J., Migliori G. B., McKenna L., Skrahina A., Tadolini M., Wilson P., Furin J. Sentinel project on pediatric drug-resistant tuberculosis. new and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations // Am. J. Respir. Crit. Care Med. ‒ 2017. ‒ Vol. 195, № 10. ‒ Р. 1300-1310. doi:10.1164/rccm.201606-1227CI.Harausz E. P., Garcia-Prats A. J., Seddon J. A., Schaaf H. S., Hesseling A. C., Achar J., Bernheimer J., Cruz A. T., D'Ambrosio L., Detjen A., Graham S. M., Hughes J., Jonckheere S., Marais B. J., Migliori G. B., McKenna L., Skrahina A., Tadolini M., Wilson P., Furin J. Sentinel project on pediatric drug-resistant tuberculosis. new and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations // Am. J. Respir. Crit. Care Med. ‒ 2017. ‒ Vol. 195, № 10. ‒ Р. 1300-1310. doi:10.1164/rccm.201606-1227CI.Hewison C., Ferlazzo G., Avaliani Z., Hayrapetyan A., Jonckheere S., Khaidarkhanova Z., Mohr E., Sinha A., Skrahina A., Vambe D., Vasilyeva I., Lachenal N., Varaine F. Six-month response to delamanid treatment in MDR TB patients // Emerg. Infect. Dis. ‒ 2017. ‒ Vol. 23, № 10. ‒ Р. 1746-1748. https://doi.org/10.3201/eid2310.170468.Hewison C., Ferlazzo G., Avaliani Z., Hayrapetyan A., Jonckheere S., Khaidarkhanova Z., Mohr E., Sinha A., Skrahina A., Vambe D., Vasilyeva I., Lachenal N., Varaine F. Six-month response to delamanid treatment in MDR TB patients // Emerg. Infect. Dis. ‒ 2017. ‒ Vol. 23, № 10. ‒ Р. 1746-1748. https://doi.org/10.3201/eid2310.170468.HIV drug interactions [website]. Liverpool, United Kingdom: University of Liverpool; 2020 (https://www.hivdruginteractions.org/checker, accessed 11 March 2020).HIV drug interactions [website]. Liverpool, United Kingdom: University of Liverpool; 2020 (https://www.hivdruginteractions.org/checker, accessed 11 March 2020).Hughes J., Reuter A., Chabalala B., Isaakidis P., Cox H., Mohr E. Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting // Int. J. Tuberc. Lung. Dis. ‒ 2019. ‒ Vol. 23, № 9. ‒ Р. 1017-1023. doi:10.5588/ijtld.18.0651.Hughes J., Reuter A., Chabalala B., Isaakidis P., Cox H., Mohr E. Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting // Int. J. Tuberc. Lung. Dis. ‒ 2019. ‒ Vol. 23, № 9. ‒ Р. 1017-1023. doi:10.5588/ijtld.18.0651.Kethireddy S., Andes D. CNS pharmacokinetics of antifungal agents // Expert. Opin. Drug. Metab. Toxicol. ‒ 2007. ‒ Vol. 3, № 4. ‒ Р. 573-581.Kethireddy S., Andes D. CNS pharmacokinetics of antifungal agents // Expert. Opin. Drug. Metab. Toxicol. ‒ 2007. ‒ Vol. 3, № 4. ‒ Р. 573-581.Kim C. T., Kim T. O., Shin H. J., Ko Y. C., Hun Choe Y., Kim H. R., Kwon Y. S. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 3. ‒ Р. 1702467. Published 2018 Mar 22. doi:10.1183/13993003.02467-2017.Kim C. T., Kim T. O., Shin H. J., Ko Y. C., Hun Choe Y., Kim H. R., Kwon Y. S. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 3. ‒ Р. 1702467. Published 2018 Mar 22. doi:10.1183/13993003.02467-2017.Lachâtre M., Rioux C., Le Dû D., Fréchet-Jachym M., Veziris N., Bouvet E., Yazdanpanah Y. Bedaquiline plus delamanid for XDR tuberculosis // Lancet Infect. Dis. ‒ 2016. ‒ Vol. 16. ‒ Р. 294.Lachâtre M., Rioux C., Le Dû D., Fréchet-Jachym M., Veziris N., Bouvet E., Yazdanpanah Y. Bedaquiline plus delamanid for XDR tuberculosis // Lancet Infect. Dis. ‒ 2016. ‒ Vol. 16. ‒ Р. 294.Li F., Lu J., Ma X. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir // Drug. Metab. Dispos. ‒ 2012. ‒ Vol. 40, № 1. ‒ Р. 18-24. doi:10.1124/dmd.111.041400.Li F., Lu J., Ma X. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir // Drug. Metab. Dispos. ‒ 2012. ‒ Vol. 40, № 1. ‒ Р. 18-24. doi:10.1124/dmd.111.041400.Li Y., Sun F., Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging // Drug. Dev. Res. ‒ 2019. ‒ Vol. 80, № 1. ‒ Р. 98-105.Li Y., Sun F., Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging // Drug. Dev. Res. ‒ 2019. ‒ Vol. 80, № 1. ‒ Р. 98-105.Mallikaarjun S., Wells C., Petersen C., Paccaly A., Shoaf S. E., Patil S., Geiter L. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects // Antimicrob. Agents. Chemother. ‒ 2016. ‒ Vol. 60, № 10. ‒ Р. 5976-5985.Mallikaarjun S., Wells C., Petersen C., Paccaly A., Shoaf S. E., Patil S., Geiter L. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects // Antimicrob. Agents. Chemother. ‒ 2016. ‒ Vol. 60, № 10. ‒ Р. 5976-5985.Maryandyshev A., Pontali E., Tiberi, S., Akkerman O., Ganatra S., Sadutshang T. D., Alffenaar J. W., Amale R., Mullerpattan J., Topgyal S., Udwadia Z. F., Centis R., D'Ambrosio L., Sotgiu G., Migliori G. B. Bedaquiline and Delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis // Emerg. Infect. Dis. ‒ 2017. ‒ Vol. 23, № 10. ‒ Р. 1718-1721. https://dx.doi.org/10.3201/eid2310.170834.Maryandyshev A., Pontali E., Tiberi, S., Akkerman O., Ganatra S., Sadutshang T. D., Alffenaar J. W., Amale R., Mullerpattan J., Topgyal S., Udwadia Z. F., Centis R., D'Ambrosio L., Sotgiu G., Migliori G. B. Bedaquiline and Delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis // Emerg. Infect. Dis. ‒ 2017. ‒ Vol. 23, № 10. ‒ Р. 1718-1721. https://dx.doi.org/10.3201/eid2310.170834.McAnaw S. E., Hesseling A. C., Seddon J. A., Dooley K. E., Garcia-Prats A. J., Kim S., Jenkins H. E., Schaaf H. S., Sterling T. R., Horsburgh C. R. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities // Int. J. Infect. Dis. ‒ 2017. ‒ Vol. 56. ‒ Р. 194-199. doi:10.1016/j.ijid.2016.11.423.McAnaw S. E., Hesseling A. C., Seddon J. A., Dooley K. E., Garcia-Prats A. J., Kim S., Jenkins H. E., Schaaf H. S., Sterling T. R., Horsburgh C. R. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities // Int. J. Infect. Dis. ‒ 2017. ‒ Vol. 56. ‒ Р. 194-199. doi:10.1016/j.ijid.2016.11.423.Migliori G. B., Pontali E., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., Tadolini M., Esposito S. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: A systematic review // Int. J. Mol. Sci. ‒ 2017. ‒ Vol. 18, № 2):341. Published 2017 Feb 7. doi:10.3390/ijms18020341.Migliori G. B., Pontali E., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., Tadolini M., Esposito S. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: A systematic review // Int. J. Mol. Sci. ‒ 2017. ‒ Vol. 18, № 2):341. Published 2017 Feb 7. doi:10.3390/ijms18020341.Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J., De Azevedo V., Kock Y., Steele S. J., Shroufi A., Ade S., Alikhanova N., Benedetti G., Edwards J., Cox H., Furin J., Isaakidis P. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 6. ‒ Р. 1800017. Published 2018 Jun 14. doi:10.1183/13993003.00017-2018.Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J., De Azevedo V., Kock Y., Steele S. J., Shroufi A., Ade S., Alikhanova N., Benedetti G., Edwards J., Cox H., Furin J., Isaakidis P. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 6. ‒ Р. 1800017. Published 2018 Jun 14. doi:10.1183/13993003.00017-2018.Mohr-Holland E., Reuter A., Furin J., Garcia-Prats A., De Azevedo V., Mudaly V., Kock Y., Trivino-Duran L., Isaakidis P., Hughes J. Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa // Clin. Med. ‒ 2020. ‒ Vol. 20. ‒ Р. 100290. doi:10.1016/j.eclinm.2020.100290.Mohr-Holland E., Reuter A., Furin J., Garcia-Prats A., De Azevedo V., Mudaly V., Kock Y., Trivino-Duran L., Isaakidis P., Hughes J. Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa // Clin. Med. ‒ 2020. ‒ Vol. 20. ‒ Р. 100290. doi:10.1016/j.eclinm.2020.100290.Mok J., Kang H., Koh W. J., Jhun B. W., Yim J. J., Kwak N., Lee T., Kang B., Jeon D. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea // Eur. Respir. J. ‒ 2019. ‒ Vol. 54. ‒ Р. 1900811 [https://doi.org/10.1183/13993003.00811-2019.Mok J., Kang H., Koh W. J., Jhun B. W., Yim J. J., Kwak N., Lee T., Kang B., Jeon D. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea // Eur. Respir. J. ‒ 2019. ‒ Vol. 54. ‒ Р. 1900811 [https://doi.org/10.1183/13993003.00811-2019.Nahid P., Mase S. R., Migliori G. B., Sotgiu G., Bothamley G. H., Brozek J. L., Cattamanchi A., Cegielski J. P., Chen L., Daley C. L., Dalton T. L., Duarte R., Fregonese F., Horsburgh C. R. Jr., Ahmad Khan F., Kheir F., Lan Z., Lardizabal A., Lauzardo M., Mangan J. M., Marks S. M., McKenna L., Menzies D., Mitnick C. D., Nilsen D. M., Parvez F., Peloquin C. A., Raftery A., Schaaf H. S., Shah N. S., Starke J. R., Wilson J. W., Wortham J. M., Chorba T., Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [published correction appears in Am J Respir Crit Care Med. 2020 Feb 15;201(4):500-501] // Am. J. Respir Crit Care Med. ‒ 2019. ‒ Vol. 200, № 10. ‒ Р. e93-e142. doi:10.1164/rccm.201909-1874ST.Nahid P., Mase S. R., Migliori G. B., Sotgiu G., Bothamley G. H., Brozek J. L., Cattamanchi A., Cegielski J. P., Chen L., Daley C. L., Dalton T. L., Duarte R., Fregonese F., Horsburgh C. R. Jr., Ahmad Khan F., Kheir F., Lan Z., Lardizabal A., Lauzardo M., Mangan J. M., Marks S. M., McKenna L., Menzies D., Mitnick C. D., Nilsen D. M., Parvez F., Peloquin C. A., Raftery A., Schaaf H. S., Shah N. S., Starke J. R., Wilson J. W., Wortham J. M., Chorba T., Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [published correction appears in Am J Respir Crit Care Med. 2020 Feb 15;201(4):500-501] // Am. J. Respir Crit Care Med. ‒ 2019. ‒ Vol. 200, № 10. ‒ Р. e93-e142. doi:10.1164/rccm.201909-1874ST.Nguyen T. V. A., Anthony R. M., Cao T. T. H., Bañuls A. L, Nguyen V. A. T., Vu D. H., Nguyen N. V., Alffenaar J. C. Delamanid resistance: update and clinical management // Clin. Infect. Dis. 2020; ciaa755. doi:10.1093/cid/ciaa755.Nguyen T. V. A., Anthony R. M., Cao T. T. H., Bañuls A. L, Nguyen V. A. T., Vu D. H., Nguyen N. V., Alffenaar J. C. Delamanid resistance: update and clinical management // Clin. Infect. Dis. 2020; ciaa755. doi:10.1093/cid/ciaa755.Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis (Protocol 242-12-232). 2013. [NCT01856634] https://clinicaltrials.gov/ct2/show/NCT01856634.Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis (Protocol 242-12-232). 2013. [NCT01856634] https://clinicaltrials.gov/ct2/show/NCT01856634.Pontali E., Centis R., D'Ambrosio L., Toscanini F., Migliori G. B. Recent evidence on delamanid use for rifampicin-resistant tuberculosis // J. Thorac. Dis. ‒ 2019. ‒ Vol. 11 (Suppl. 3). ‒ Р. S457-S460. doi:10.21037/jtd.2018.11.26.Pontali E., Centis R., D'Ambrosio L., Toscanini F., Migliori G. B. Recent evidence on delamanid use for rifampicin-resistant tuberculosis // J. Thorac. Dis. ‒ 2019. ‒ Vol. 11 (Suppl. 3). ‒ Р. S457-S460. doi:10.21037/jtd.2018.11.26.Pontali E., Sotgiu G., Tiberi S., Tadolini M., Visca D., D'Ambrosio L., Centis R., Spanevello A., Migliori G. B. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: A systematic review // Eur. Respir. J. 2018. ‒ Vol. 52, № 1. ‒ Р. 1800934. Published 2018 Jul 4. doi:10.1183/13993003.00934-2018.Pontali E., Sotgiu G., Tiberi S., Tadolini M., Visca D., D'Ambrosio L., Centis R., Spanevello A., Migliori G. B. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: A systematic review // Eur. Respir. J. 2018. ‒ Vol. 52, № 1. ‒ Р. 1800934. Published 2018 Jul 4. doi:10.1183/13993003.00934-2018.Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) [NCT03568383] https://clinicaltrials.gov/ct2/show/NCT03568383.Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) [NCT03568383] https://clinicaltrials.gov/ct2/show/NCT03568383.Resist-TB. Drug resistant TB clinical trials progress report, http://www.resisttb.org/?page_id=1602.Resist-TB. Drug resistant TB clinical trials progress report, http://www.resisttb.org/?page_id=1602.Rodriguez C. A., Brooks M. B., Guglielmetti L., Hewison C., Jachym M. F., Lessem E., Varaine F, Mitnick C. D. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study // Public. Health Action. ‒ 2019. ‒ Vol. 9, № 1. ‒ Р. 32-41. doi:10.5588/pha.18.0078.Rodriguez C. A., Brooks M. B., Guglielmetti L., Hewison C., Jachym M. F., Lessem E., Varaine F, Mitnick C. D. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study // Public. Health Action. ‒ 2019. ‒ Vol. 9, № 1. ‒ Р. 32-41. doi:10.5588/pha.18.0078.Safety and Efficacy Trial of Delamanid for 6 Months in Participants with Multidrug-Resistant Tuberculosis [NCT01424670] https://clinicaltrials.gov/ct2/show/NCT01424670.Safety and Efficacy Trial of Delamanid for 6 Months in Participants with Multidrug-Resistant Tuberculosis [NCT01424670] https://clinicaltrials.gov/ct2/show/NCT01424670.Sasahara K., Shimokawa Y., Hirao Y., Koyama N., Kitano K., Shibata M., Umehara K. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo // Drug. Metab. Dispos. ‒ 2015. ‒ Vol. 43, № 8. ‒ Р. 1267-1276. doi:10.1124/dmd.115.064527.Sasahara K., Shimokawa Y., Hirao Y., Koyama N., Kitano K., Shibata M., Umehara K. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo // Drug. Metab. Dispos. ‒ 2015. ‒ Vol. 43, № 8. ‒ Р. 1267-1276. doi:10.1124/dmd.115.064527.Seddon J. A., Schaaf H. S., Marais B. J., McKenna L., Garcia-Prats A. J., Hesseling A. C., Hughes J., Howell P., Detjen A., Amanullah F., Singh U., Master I., Perez-Velez C. M., Misra N., Becerra M. C., Furin J. J. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis // Lancet Respir. Med. ‒ 2018. ‒ Vol. 6, № 9. ‒ Р. 662-664. doi:10.1016/S2213-2600(18)30329-1.Seddon J. A., Schaaf H. S., Marais B. J., McKenna L., Garcia-Prats A. J., Hesseling A. C., Hughes J., Howell P., Detjen A., Amanullah F., Singh U., Master I., Perez-Velez C. M., Misra N., Becerra M. C., Furin J. J. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis // Lancet Respir. Med. ‒ 2018. ‒ Vol. 6, № 9. ‒ Р. 662-664. doi:10.1016/S2213-2600(18)30329-1.Shibata M., Shimokawa Y., Sasahara K., Yoda N., Sasabe H., Suzuki M., Umehara K. Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis // Biopharm. Drug. Dispos. ‒ 2017. ‒ Vol. 38, № 4. ‒ Р. 301-312.Shibata M., Shimokawa Y., Sasahara K., Yoda N., Sasabe H., Suzuki M., Umehara K. Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis // Biopharm. Drug. Dispos. ‒ 2017. ‒ Vol. 38, № 4. ‒ Р. 301-312.Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., Cirule A., Leimane V., Kurve A., Levina K., Geiter L. J., Manissero D., Wells C. D. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis // Eur. Respir. J. ‒ 2013. ‒ Vol. 41. ‒ Р. 1393-1400; DOI: 10.1183/09031936.00125812.Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., Cirule A., Leimane V., Kurve A., Levina K., Geiter L. J., Manissero D., Wells C. D. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis // Eur. Respir. J. ‒ 2013. ‒ Vol. 41. ‒ Р. 1393-1400; DOI: 10.1183/09031936.00125812.Szumowski J. D., Lynch J. B. Profile of delamanid for the treatment of multidrug-resistant tuberculosis // Drug. Des. Devel. Ther. ‒ 2015. ‒ Vol. 9. ‒ Р. 677-682. doi:10.2147/DDDT.S60923.Szumowski J. D., Lynch J. B. Profile of delamanid for the treatment of multidrug-resistant tuberculosis // Drug. Des. Devel. Ther. ‒ 2015. ‒ Vol. 9. ‒ Р. 677-682. doi:10.2147/DDDT.S60923.Tadolini M., Garcia-Prats A. J., D'Ambrosio L., Hewison C., Centis R., Schaaf H. S., Marais B. J., Ferreira H., Caminero J. A., Jonckheere S., Sinha A., Herboczek K., Khaidarkhanova Z., Hayrapetyan A., Khachatryan N., Urtkmelidze Ia., Loreti C., Esposito S., Matteelli A., Furin J., Varaine F., Migliori G. B. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges // Eur. Respir. J. ‒ 2016. ‒ Vol. 48, № 3. ‒ Р. 938-943. doi:10.1183/13993003.00705-2016.Tadolini M., Garcia-Prats A. J., D'Ambrosio L., Hewison C., Centis R., Schaaf H. S., Marais B. J., Ferreira H., Caminero J. A., Jonckheere S., Sinha A., Herboczek K., Khaidarkhanova Z., Hayrapetyan A., Khachatryan N., Urtkmelidze Ia., Loreti C., Esposito S., Matteelli A., Furin J., Varaine F., Migliori G. B. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges // Eur. Respir. J. ‒ 2016. ‒ Vol. 48, № 3. ‒ Р. 938-943. doi:10.1183/13993003.00705-2016.Tadolini M., Lingtsang R. D., Tiberi S., Enwerem M., D'Ambrosio L., Sadutshang T. D., Centis R., Migliori G. B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Eur. Respir. J. ‒ 2016. ‒ Vol. 48. ‒ Р. 935-938.Tadolini M., Lingtsang R. D., Tiberi S., Enwerem M., D'Ambrosio L., Sadutshang T. D., Centis R., Migliori G. B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Eur. Respir. J. ‒ 2016. ‒ Vol. 48. ‒ Р. 935-938.Tucker E. W., Pieterse L., Zimmerman M. D., Udwadia Z. F., Peloquin C. A., Gler M. T., Ganatra S., Tornheim J. A., Chawla P., Caoili J. C., Ritchie B., Jain S. K., Dartois V., Dooley K. E. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans // Antimicrob. Agents Chemother. ‒ 2019. ‒ Vol. 63, № 10. ‒ Р. e00913- e00919. Published 2019 Sep 23. doi:10.1128/AAC.00913-19].Tucker E. W., Pieterse L., Zimmerman M. D., Udwadia Z. F., Peloquin C. A., Gler M. T., Ganatra S., Tornheim J. A., Chawla P., Caoili J. C., Ritchie B., Jain S. K., Dartois V., Dooley K. E. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans // Antimicrob. Agents Chemother. ‒ 2019. ‒ Vol. 63, № 10. ‒ Р. e00913- e00919. Published 2019 Sep 23. doi:10.1128/AAC.00913-19].von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr, Ticona E., Segura P., Cadena E., Yu C., Cirule A., Lizarbe V., Davidaviciene E., Domente L., Variava E., Caoili J., Danilovits M., Bielskiene V., Staples S., Hittel N., Petersen C., Wells C., Hafkin J., Geiter L. J., Gupta R. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Trial 213 // Lancet Respir. Med. ‒ 2019. ‒ Vol. 7, № 3. ‒ Р. 249-259.von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr, Ticona E., Segura P., Cadena E., Yu C., Cirule A., Lizarbe V., Davidaviciene E., Domente L., Variava E., Caoili J., Danilovits M., Bielskiene V., Staples S., Hittel N., Petersen C., Wells C., Hafkin J., Geiter L. J., Gupta R. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Trial 213 // Lancet Respir. Med. ‒ 2019. ‒ Vol. 7, № 3. ‒ Р. 249-259.Wen S., Jing W., Zhang T., Zong Z., Xue Y., Shang Y., Wang F., Huang H., Chu N., Pang Y. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. ‒ 2019. ‒ Vol. 38, № 7. ‒ Р. 1293-1296. doi:10.1007/s10096-019-03551-w.Wen S., Jing W., Zhang T., Zong Z., Xue Y., Shang Y., Wang F., Huang H., Chu N., Pang Y. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. ‒ 2019. ‒ Vol. 38, № 7. ‒ Р. 1293-1296. doi:10.1007/s10096-019-03551-w.World Health Organization (WHO). (2017). WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. World Health Organization, 2017 https://apps.who.int/iris/handle/10665/258941. License: CC BY-NC-SA 3.0 IGO.World Health Organization (WHO). (2017). WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. World Health Organization, 2017 https://apps.who.int/iris/handle/10665/258941. License: CC BY-NC-SA 3.0 IGO.World Health Organization (WHO). Ethics guidance for the implementation of the End TB Strategy (WHO/HTM/TB/2017.07) [Internet]. Geneva, World Health Organization. 2017. Available from: http://apps.who.int/iris/bitstream/10665/254820/1/9789241512114-eng.pdf.World Health Organization (WHO). Ethics guidance for the implementation of the End TB Strategy (WHO/HTM/TB/2017.07) [Internet]. Geneva, World Health Organization. 2017. Available from: http://apps.who.int/iris/bitstream/10665/254820/1/9789241512114-eng.pdf.World Health Organization (WHO). The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance. Geneva: World Health Organization; 2016.World Health Organization (WHO). The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance. Geneva: World Health Organization; 2016.World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020]. 61. World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 4: treatment ‒ drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020]. 61. World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 4: treatment ‒ drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.

The authors declare that there are no conflicts of interest present.